Treatment for HIV infection, and used as part of a 3-drug combination regimen.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Monitor hyperglycemia and new onset or worsening diabetes mellitus during treatment for all patients.
Monitor ALT,AST, and total bilirubin.
Common
Serious
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral agent, Protease inhibitor
Pregnancy category: C
Average serum half life: 3.67-6.1 hours
Precautions: Avoid use in patients with congenital long QT syndrome or hypokalemia. Avoid use with QT interval-prolonging drugs.
Large elevations of triglycerides and cholesterol has been reported; monitoring recommended. Consider monitoring for hyperglycemia and new onset or exacerbation of diabetes mellitus.
Use of the oral solution in preterm neonates in the immediate postnatal period is not recommended due to potential adverse effects caused by propylene glycol accumulation.